Research programme: G protein-coupled receptor modulating small molecules - Omeros

Drug Profile

Research programme: G protein-coupled receptor modulating small molecules - Omeros

Alternative Names: GPR101-targeting compounds - Omeros; GPR151-targeting compounds - Omeros; GPR161-targeting compounds - Omeros; GPR17-targeting compounds - Omeros; GPR174-targeting compounds - Omeros; GPR183-targeting compounds - Omeros

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Omeros Corporation
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor agonists; G protein-coupled receptor antagonists; Neuromedin U receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cognition disorders; Demyelinating disorders; Eating disorders; Epstein-Barr virus infections; Metabolic disorders; Osteoporosis; Pain
  • No development reported Autistic disorder; Gastrointestinal disorders; Inflammation; Multiple sclerosis; Obesity; Psychotic disorders; Rheumatoid arthritis; Sleep disorders

Most Recent Events

  • 16 Mar 2017 Omeros Corporation has patent protection for GPCR platform in USA and ex-US countries
  • 05 Dec 2016 Pharmacodynamics data from preclinical trials in Cancer released by Omeros
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top